Fosigotifator is under clinical development by Calico Life Sciences and currently in Phase II for Unspecified Central Nervous System Disorders. According to GlobalData, Phase II drugs for Unspecified Central Nervous System Disorders have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Fosigotifator’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Fosigotifator overview
ABBVCLS-7262 is under development for the treatment of amyotrophic lateral sclerosis (ALS), major depressive disorder and vanishing white matter disease in adults and pediatrics. The drug candidate acts by targeting eukaryotic translation initiation factor 2 subunit beta (EIF2B). It is administered through oral route.
Calico Life Sciences overview
Calico Life Sciences (Calico), a subsidiary of Alphabet Inc, is a research and development company. It focuses on the development, discovery, and commercialization of therapies for treating diseases of aging including neurodegeneration and cancer. The company is investing in the investigational eIF2B activator Fosigotifator (ABBV-CLS-7262) for the treatment of vanishing white matter disease. It is also developing ABBV-CLS-579 and ABBV-CLS-484 for the indication of locally advanced or metastatic tumors. Calico partners with organizations like the Broad Institute and AbbVie to advance its drug discovery and development programs. Calico is headquartered in South San Francisco, California, the US.
For a complete picture of Fosigotifator’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
